Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

医学 中止 内科学 临床终点 耐火材料(行星科学) 临床研究阶段 淋巴瘤 胃肠病学 肿瘤科 临床试验 天体生物学 物理
作者
Yuqin Song,Luis Malpica,Qingqing Cai,Weili Zhao,Keshu Zhou,Jianqiu Wu,Huilai Zhang,Neha Mehta‐Shah,Kaiyang Ding,Yao Liu,Zengjun Li,Liling Zhang,Meifang Zheng,Jie Jin,Haiyan Yang,Yue-Rong Shuang,Dok Hyun Yoon,Sujun Gao,Wenyu Li,Zhimin Zhai
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (1): 117-125 被引量:19
标识
DOI:10.1016/s1470-2045(23)00589-2
摘要

Background Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, has shown encouraging anti-tumour activity in heavily pre-treated patients with relapsed or refractory peripheral T-cell lymphoma in a phase 1 study (JACKPOT8 Part A). Here, we report the full analysis of a phase 2 study, in which we assessed the anti-tumour activity of golidocitinib in a large multinational cohort of patients. Methods We did a single-arm, multinational, phase 2 trial (JACKPOT8 Part B) in 49 centres in Australia, China, South Korea, and the USA. Eligible patients were adults (aged ≥18 years) with relapsed or refractory peripheral T-cell lymphoma who had received at least one previous line of systemic therapy and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were given oral golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met. The primary endpoint was the CT-based objective response rate, assessed by an independent review committee (IRC) per Lugano 2014 classification. The activity analysis set included all patients who received at least one dose and whose pathological diagnosis of peripheral T-cell lymphoma had been retrospectively confirmed by a central laboratory and who had at least one measurable lesion at baseline assessed by IRC. The safety analysis set included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04105010, and is closed to accrual and follow-up is ongoing. Findings Between Feb 26, 2021, and Oct 12, 2022, we assessed 161 patients for eligibility, of whom 104 (65%) were enrolled and received at least one dose of study drug; the activity analysis set included 88 (85%) patients (median age 58 years [IQR 51–67], 57 [65%] of 88 were male, 31 [35%] were female, and 83 [94%] were Asian). As of data cutoff (Aug 31, 2023; median follow-up was 13·3 months [IQR 4·9–18·4]), per IRC assessment, the objective response rate was 44·3% (95% CI 33·7–55·3; 39 of 88 patients, p<0·0001), with 21 (24%) patients having a complete response and 18 (20%) having a partial response. In the safety analysis set, 61 (59%) of 104 patients had grade 3–4 drug-related treatment-emergent adverse events. The most common grade 3–4 drug-related treatment-emergent adverse events were neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. 25 (24%) patients had treatment-related serious adverse events. Deaths due to treatment-emergent adverse events occurred in three (3%) patients: two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. Interpretation In this phase 2 study, golidocitinib showed a favourable benefit–risk profile in treating relapsed or refractory peripheral T-cell lymphoma. The results of this study warrant further randomised clinical studies to confirm activity and assess efficacy in this population. Funding Dizal Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI5应助nteicu采纳,获得10
刚刚
刚刚
华仔应助忧郁盼夏采纳,获得10
1秒前
mark163完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
1秒前
1秒前
科研通AI2S应助斯文以蓝采纳,获得10
1秒前
Qian发布了新的文献求助10
1秒前
ZL张莉发布了新的文献求助10
1秒前
Camellia完成签到,获得积分10
2秒前
2秒前
lovehao完成签到 ,获得积分10
2秒前
silstorm发布了新的文献求助10
2秒前
失眠夏山发布了新的文献求助20
2秒前
rich完成签到,获得积分10
2秒前
ANXU完成签到,获得积分20
3秒前
yangyang发布了新的文献求助10
3秒前
中岛悠斗完成签到,获得积分10
3秒前
香蕉发布了新的文献求助10
3秒前
雪原白鹿完成签到 ,获得积分10
3秒前
自信的网络完成签到 ,获得积分10
3秒前
Jin完成签到,获得积分10
3秒前
strangeliu完成签到,获得积分10
3秒前
落后紫夏完成签到,获得积分10
4秒前
4秒前
00K发布了新的文献求助10
5秒前
zzz完成签到,获得积分10
5秒前
6秒前
栗子发布了新的文献求助10
6秒前
6秒前
懦弱的咖啡豆完成签到,获得积分10
6秒前
6秒前
ZMY发布了新的文献求助10
7秒前
TTT0530完成签到,获得积分10
7秒前
复杂语山完成签到,获得积分10
7秒前
香蕉觅云应助chcmuer采纳,获得10
7秒前
666关闭了666文献求助
7秒前
8秒前
8秒前
jignjing完成签到,获得积分10
8秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969033
求助须知:如何正确求助?哪些是违规求助? 3513900
关于积分的说明 11170818
捐赠科研通 3249256
什么是DOI,文献DOI怎么找? 1794708
邀请新用户注册赠送积分活动 875326
科研通“疑难数据库(出版商)”最低求助积分说明 804759